Xencor, Inc.

Amgen Inc.

United States Postal Service

The Bodygym Corporation

Gregory L Moore

John R Desjarlais

Matthew J Bernett

Rumana Rashid

Seung Yup Chu

Umesh Muchhal

Sung-Hyung Lee

Gregory Alan Lazar

Michael Hedvat

Sher Bahadur Karki

Alex Nisthal

Igor Vostiar

Christine Bonzon

Juan Diaz

Jonathan Zalevsky

Arthur J Chirino

Duc-Hanh Thi Nguyen

Veronica Gusti Zeng

Sergei A Ezhevsky

Darian Cash

Rajat Varma

Paul Foster

Adam Zwolak

Ke Liu

Fei Shen

Matthew Adam Dragovich

Yoon Kyung Kim

Joseph Erhardt

Fouad Moussa

Eric Chang

Pankaj Seth

Theresa McDevitt

Derrick Johnson

Neeraj Jagdish Agrawal

Kevin Graham

Christopher Murawsky

John O Richards

Jennitte LeAnn Stevens

Benjamin M Alba

David F Carmichael

Olivier Nolan-Stevaux

Cong Li

Umesh S Muchhal

Mercedesz Balazs

Dexter Williams

Susan Mcmeen

John Deslarlais

John Owen Richards

David Forrester Carmichael

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains

In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

Heterodimeric proteins

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Bispecific binding agents binding to CLDN18.2 and CD3

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

The present invention is directed to novel heterodimeric antibodies.

Heterodimeric antibodies that bind CD3 and tumor antigens

The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

Heterodimeric antibodies that bind CD3 and CD38

The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).

Heterodimeric antibodies that bind somatostatin receptor 2

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

Provided herein are novel anti-CD28×anti-B7H3 (also referred to as 'αCD28×αB7H3') heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

Anti-CD28 compositions

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Bispecific antibodies that bind to CD38 and CD3

Growing community of inventors

Pasadena, CA, United States of America

Gregory L Moore